MARKET

IBIO

IBIO

Ibio
AMEX
2.150
-0.100
-4.44%
Opening 15:05 05/23 EDT
OPEN
2.210
PREV CLOSE
2.250
HIGH
2.260
LOW
2.060
VOLUME
148.16K
TURNOVER
0
52 WEEK HIGH
19.20
52 WEEK LOW
1.021
MARKET CAP
18.54M
P/E (TTM)
-0.1258
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at IBIO last week (0513-0517)?
Weekly Report · 3d ago
IBIO Stock Earnings: iBio Reported Results for Q3 2024
IBio reported results for the third quarter of 2024. The company did not report any revenue for the quarter. IBio reported earnings per share of -71 cents and no revenue. IBio is a biopharmaceutical company based in New York.
Investorplace · 05/14 00:56
iBio reports Q3 results
Seeking Alpha · 05/13 21:12
iBio Q3 EPS $(0.71) Up From $(9.53) YoY
Benzinga · 05/13 20:13
Press Release: iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
IBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update. Strengthened cash position with investment by healthcare specialist investors. Expanding into cardio-metabolic space through AstralBio collaboration. IBio is an AI-driven innovator of precision antibody immunotherapies.
Dow Jones · 05/13 20:05
Weekly Report: what happened at IBIO last week (0506-0510)?
Weekly Report · 05/13 09:42
Weekly Report: what happened at IBIO last week (0429-0503)?
Weekly Report · 05/06 09:44
Weekly Report: what happened at IBIO last week (0422-0426)?
Weekly Report · 04/29 09:45
More
About IBIO
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. It is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, and CCR8. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

Webull offers Ibio Inc stock information, including AMEX: IBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IBIO stock methods without spending real money on the virtual paper trading platform.